SIRT1 Protects Dopaminergic Neurons in Parkinson’s Disease Models via PGC-1α-Mediated Mitochondrial Biogenesis

被引:0
作者
Yu Chen
Yuhui Jiang
Yinuo Yang
Xinzhong Huang
Cheng Sun
机构
[1] Affiliated Hospital of Nantong University,Department of Emergency Medicine
[2] Nantong University,Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education NMPA Key Laboratory for Research and Evaluation of Tissue Engineering Technology Products
[3] Affiliated Hospital of Nantong University,Department of Nephrology
[4] Nantong Key Laboratory of Translational Medicine in Cardiothoracic Diseases,undefined
[5] Institute of Translational Medicine in Cardiothoracic Diseases,undefined
[6] Affiliated Hospital of Nantong University,undefined
来源
Neurotoxicity Research | 2021年 / 39卷
关键词
SIRT1; Dopaminergic neurons; PGC-1α; Mitochondrial biogenesis; Parkinson’s disease;
D O I
暂无
中图分类号
学科分类号
摘要
SIRT1 is a deacetylase with multiple physiological functions by targeting histones and non-histone proteins. It has been shown that SIRT1 activation is involved in neuroprotection in Parkinson’s disease (PD) models. In the present study, we provided direct evidences showing the neuroprotective roles of SIRT1 in dopaminergic neurons. Our data showed that increased expression of SIRT1 plays beneficial roles against MPP+ insults in SH-SY5Y cells and primary dopaminergic neurons, including increased cell viability, reduced LDH release, improved the mitochondrial membrane potential (MMP), and attenuated cell apoptosis. On the contrary, knockdown of SIRT1 further aggravated cell injuries induced by MPP+. Moreover, mutated SIRT1 without deacetylase activity (SIRT1 H363Y) failed to protect dopaminergic neurons from MPP+ injuries. Mechanistically, SIRT1 improved PGC-1α expression and mitochondrial biogenesis. Knockdown of PGC-1α almost completely abolished the neuroprotective roles of SIRT1 in SH-SY5Y cells. Collectively, our data indicate that SIRT1 has neuroprotective roles in dopaminergic neurons, which is dependent upon PGC-1α-mediated mitochondrial biogenesis. These findings suggest that SIRT1 may hold great therapeutic potentials for treating dopaminergic neuron loss associated disorders such as PD.
引用
收藏
页码:1393 / 1404
页数:11
相关论文
共 255 条
[11]  
de Vos RA(2003)Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan Nature 425 191-1005
[12]  
Jansen Steur EN(2014)Sirt1 activation ameliorates renal fibrosis by inhibiting the TGF-beta/Smad3 pathway J Cell Biochem 115 996-2580
[13]  
Braak E(1999)The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms Genes Dev 13 2570-912
[14]  
Brunet A(2015)Parkinson’s disease Lancet 386 896-78
[15]  
Sweeney LB(2015)Sirt1 in cerebral ischemia Brain Circ 1 69-1260
[16]  
Sturgill JF(2011)p38 MAPK-mediated regulation of Xbp1s is crucial for glucose homeostasis Nature Medicine 17 1251-438
[17]  
Chua KF(2006)GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1alpha Cell Metab 3 429-221
[18]  
Greer PL(2015)Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson's disease Behav Brain Res 281 215-716
[19]  
Lin Y(2007)Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes Nature 450 712-1165
[20]  
Tran H(2012)Transgenic expression and activation of PGC-1alpha protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease Cell Mol Life Sci 69 1153-918